{
    "ticker": "PTLO",
    "name": "Portola Pharmaceuticals, Inc.",
    "description": "Portola Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of innovative therapies for patients with rare and serious medical conditions. Founded in 2003, the company is focused on advancing novel anticoagulant and bleeding control therapies, addressing unmet medical needs in the field of hematology. Portola's flagship product, Andexxa, is a groundbreaking reversal agent for the anticoagulant drug apixaban and rivaroxaban, used in cases of life-threatening bleeding. The company is committed to improving the safety and efficacy of anticoagulant therapies and enhancing patient outcomes through its research and development efforts. In addition to Andexxa, Portola is working on other pipeline products aimed at providing solutions for patients requiring urgent reversal of anticoagulation. The company\u2019s mission emphasizes innovation, dedication to patient care, and collaboration with healthcare professionals to ensure that patients receive the best possible treatment options. Portola's leadership team comprises experienced professionals from the biopharmaceutical industry, fully aligned with the company's vision to reduce the burden of bleeding complications for patients.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "South San Francisco, California, USA",
    "founded": "2003",
    "website": "https://www.portola.com",
    "ceo": "William Lis",
    "social_media": {
        "twitter": "https://twitter.com/PortolaPharma",
        "linkedin": "https://www.linkedin.com/company/portola-pharmaceuticals/"
    },
    "investor_relations": "https://investors.portola.com",
    "key_executives": [
        {
            "name": "William Lis",
            "position": "CEO"
        },
        {
            "name": "John A. R. Walker",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Anticoagulant Reversal Agents",
            "products": [
                "Andexxa"
            ]
        }
    ],
    "seo": {
        "meta_title": "Portola Pharmaceuticals, Inc. | Innovative Therapies for Hematology",
        "meta_description": "Explore Portola Pharmaceuticals, Inc., a leader in developing innovative therapies for serious medical conditions. Learn about our commitment to patient care and groundbreaking products.",
        "keywords": [
            "Portola Pharmaceuticals",
            "Andexxa",
            "Anticoagulant Reversal",
            "Biopharmaceuticals",
            "Hematology"
        ]
    },
    "faq": [
        {
            "question": "What is Portola Pharmaceuticals known for?",
            "answer": "Portola Pharmaceuticals is known for its innovative therapies in anticoagulation and bleeding control, particularly its product Andexxa."
        },
        {
            "question": "Who is the CEO of Portola Pharmaceuticals?",
            "answer": "William Lis is the CEO of Portola Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Portola Pharmaceuticals headquartered?",
            "answer": "Portola Pharmaceuticals is headquartered in South San Francisco, California, USA."
        },
        {
            "question": "What is Andexxa?",
            "answer": "Andexxa is a reversal agent for the anticoagulant drugs apixaban and rivaroxaban, used in emergencies to control life-threatening bleeding."
        },
        {
            "question": "When was Portola Pharmaceuticals founded?",
            "answer": "Portola Pharmaceuticals was founded in 2003."
        }
    ],
    "competitors": [
        "RHHBY",
        "BMY",
        "NVS"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "ABBV"
    ]
}